1	HOUSE OF REPRESENTATIVES - FLOOR VERSION										
2	STATE OF OKLAHOMA										
3	2nd Session of the 57th Legislature (2020)										
4	HOUSE BILL 2852 By: Pae of the House										
5	and										
6	Pugh of the Senate										
7											
8											
9	AS INTRODUCED										
10											
11	Department of Health to apply for approval of program in accordance with 21 U.S.C., Section 384 for importation of prescription drugs; providing deadline for application; authorizing establishment of fee; providing list of prohibited activities; providing for codification; and providing an effective date.										
12											
13											
14											
15											
16	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:										
17	SECTION 1. NEW LAW A new section of law to be codified										
18	in the Oklahoma Statutes as Section 1-1432 of Title 63, unless there										
19	is created a duplication in numbering, reads as follows:										
20	A. The State Department of Health shall make application to the										
21	United States Secretary of Health and Human Services for approval of										
22	a program in full accordance with the provisions of 21 U.S.C.,										
23	Section 384 and shall determine the appropriate rules and										
24											

1	regulations	to	apply	for	and	administer	the	program	upon	approva	ιJ
2	from the Uni	tec	d State	28 Se	ecret	ary of Hea	l+h ;	and Humar	n Serv	<i>i</i> ices	

- B. The application shall be submitted no later than July 1, 4 2021.
 - C. The State Department of Health is authorized to establish a nominal fee per unit of drug to cover only costs necessary to efficiently administer the program and not jeopardize consumer savings.
 - D. In conjunction with this section, pharmaceutical manufacturers shall be prohibited from engaging in any of the following activities:
 - 1. Taking any action, by agreement, unilaterally, or otherwise, that has the effect of fixing or otherwise controlling the price that a pharmaceutical supplier, distributor or dispenser charges or advertises for pharmaceuticals in the program; and
 - 2. Discriminating against a pharmaceutical supplier, distributor or dispenser based on whether the supplier, distributor or dispenser participates in the program.
- SECTION 2. This act shall become effective November 1, 2020.

COMMITTEE REPORT BY: COMMITTEE ON PUBLIC HEALTH, dated 02/19/2020 - DO PASS, As Coauthored.